BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Merlin S, Famà R, Borroni E, Zanolini D, Bruscaggin V, Zucchelli S, Follenzi A. FVIII expression by its native promoter sustains long-term correction avoiding immune response in hemophilic mice. Blood Adv 2019;3:825-38. [PMID: 30862611 DOI: 10.1182/bloodadvances.2018027979] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Cormier M, Batty P, Tarrant J, Lillicrap D. Advances in knowledge of inhibitor formation in severe haemophilia A. Br J Haematol 2020;189:39-53. [DOI: 10.1111/bjh.16377] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
2 Arruda VR, Weber J, Samelson-Jones BJ. Gene Therapy for Inherited Bleeding Disorders. Semin Thromb Hemost 2021;47:161-73. [PMID: 33636747 DOI: 10.1055/s-0041-1722862] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Gage BK, Merlin S, Olgasi C, Follenzi A, Keller GM. Therapeutic correction of hemophilia A by transplantation of hPSC-derived liver sinusoidal endothelial cell progenitors. Cell Rep 2022;39:110621. [PMID: 35385743 DOI: 10.1016/j.celrep.2022.110621] [Reference Citation Analysis]
4 Shi Q, Carman CV, Chen Y, Sage PT, Xue F, Liang XM, Gilbert GE. Unexpected enhancement of FVIII immunogenicity by endothelial expression in lentivirus-transduced and transgenic mice. Blood Adv 2020;4:2272-85. [PMID: 32453842 DOI: 10.1182/bloodadvances.2020001468] [Reference Citation Analysis]
5 Neumeyer J, Lin RZ, Wang K, Hong X, Hua T, Croteau SE, Neufeld EJ, Melero-Martin JM. Bioengineering hemophilia A-specific microvascular grafts for delivery of full-length factor VIII into the bloodstream. Blood Adv 2019;3:4166-76. [PMID: 31851760 DOI: 10.1182/bloodadvances.2019000848] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
6 Zhou M, Hu Z, Zhang C, Wu L, Li Z, Liang D. Gene Therapy for Hemophilia A: Where We Stand. Curr Gene Ther 2020;20:142-51. [PMID: 32767930 DOI: 10.2174/1566523220666200806110849] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Merlin S, Follenzi A. Escape or Fight: Inhibitors in Hemophilia A. Front Immunol 2020;11:476. [PMID: 32265927 DOI: 10.3389/fimmu.2020.00476] [Reference Citation Analysis]
8 Famà R, Borroni E, Zanolini D, Merlin S, Bruscaggin V, Walker GE, Olgasi C, Babu D, Agnelli Giacchello J, Valeri F, Giordano M, Borchiellini A, Follenzi A. Identification and functional characterization of a novel splicing variant in the F8 coagulation gene causing severe hemophilia A. J Thromb Haemost 2020;18:1050-64. [PMID: 32078252 DOI: 10.1111/jth.14779] [Reference Citation Analysis]
9 Famà R, Borroni E, Merlin S, Airoldi C, Pignani S, Cucci A, Corà D, Bruscaggin V, Scardellato S, Faletti S, Pelicci G, Pinotti M, Walker GE, Follenzi A. Deciphering the Ets-1/2-mediated transcriptional regulation of F8 gene identifies a minimal F8 promoter for hemophilia A gene therapy. Haematologica 2021;106:1624-35. [PMID: 32467137 DOI: 10.3324/haematol.2019.239202] [Reference Citation Analysis]
10 Simioni P, Cagnin S, Sartorello F, Sales G, Pagani L, Bulato C, Gavasso S, Nuzzo F, Chemello F, Radu CM, Tormene D, Spiezia L, Hackeng TM, Campello E, Castoldi E. Partial F8 gene duplication (factor VIII Padua) associated with high factor VIII levels and familial thrombophilia. Blood 2021;137:2383-93. [PMID: 33275657 DOI: 10.1182/blood.2020008168] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Gong J, Chung TH, Zheng J, Zheng H, Chang LJ. Transduction of modified factor VIII gene improves lentiviral gene therapy efficacy for hemophilia A. J Biol Chem 2021;297:101397. [PMID: 34774524 DOI: 10.1016/j.jbc.2021.101397] [Reference Citation Analysis]
12 Patel SR, Lundgren TS, Spencer HT, Doering CB. The Immune Response to the fVIII Gene Therapy in Preclinical Models. Front Immunol 2020;11:494. [PMID: 32351497 DOI: 10.3389/fimmu.2020.00494] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]